These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 11857520

  • 21. Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B.
    Tsubota A, Arase Y, Suzuki F, Kobayashi M, Matsuda M, Sato J, Suzuki Y, Akuta N, Sezaki H, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kumada H.
    J Med Virol; 2004 May; 73(1):7-12. PubMed ID: 15042641
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
    Yuen MF, Fung J, Seto WK, Wong DK, Yuen JC, Lai CL.
    Antivir Ther; 2009 May; 14(5):679-85. PubMed ID: 19704171
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.
    Lai CL, Rosmawati M, Lao J, Van Vlierberghe H, Anderson FH, Thomas N, Dehertogh D.
    Gastroenterology; 2002 Dec; 123(6):1831-8. PubMed ID: 12454840
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Durability of serologic response after lamivudine treatment of chronic hepatitis B.
    Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, Woessner M, Gardner S, Schiff E.
    Hepatology; 2003 Apr; 37(4):748-55. PubMed ID: 12668966
    [Abstract] [Full Text] [Related]

  • 31. [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients].
    Zhu M, Xu B, Yao GB.
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):534-6. PubMed ID: 16042894
    [Abstract] [Full Text] [Related]

  • 32. Short-term lamivudine therapy in HBeAg-negative chronic active hepatitis B in Taiwan.
    Chien RN, Liaw YF.
    Antivir Ther; 2006 Jul; 11(7):947-52. PubMed ID: 17302259
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression.
    Yeh CT, Hsu CW, Chen YC, Liaw YF.
    J Clin Virol; 2009 Jun; 45(2):114-8. PubMed ID: 19451024
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Clinical trial results and treatment resistance with lamivudine in hepatitis B.
    Wright TL.
    Semin Liver Dis; 2004 Jun; 24 Suppl 1():31-6. PubMed ID: 15192799
    [Abstract] [Full Text] [Related]

  • 38. [Relationship between B virus hepatitis genotypes and therapeutic efficacy in early treatment for chronic hepatitis B by using lamivudine].
    Song SJ, Zhuang H, Yan J, Wei HS, He ZP, Song C, Dong QM, Xiao YP.
    Zhonghua Yu Fang Yi Xue Za Zhi; 2005 May; 39(3):203-5. PubMed ID: 15938857
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B.
    Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kobayashi M, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kawamura Y, Kobayashi M, Kumada H.
    J Med Virol; 2007 Sep; 79(9):1286-92. PubMed ID: 17607775
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.